A strain of Ebola spreading through Congo and Uganda has no licensed vaccine, leaving health authorities scrambling to contain an outbreak that has already killed dozens and exposing critical gaps in pandemic preparedness despite lessons from COVID-19 and previous Ebola epidemics.

The variant differs from the West African strain for which vaccines were developed during the 2014-2016 epidemic, according to Medical Xpress, leaving health workers to rely on isolation, contact tracing, and supportive care - the same tools used before modern vaccines existed. The outbreak comes as U.S. public health funding cuts ongoing, diminishing international response capacity precisely when coordination is most needed.

To understand today's headlines, we must look at yesterday's decisions. The 2014-2016 Ebola outbreak in West Africa killed more than 11,000 people and prompted accelerated vaccine development. The resulting vaccines, particularly rVSV-ZEBOV (marketed as Ervebo), proved highly effective and were deployed during subsequent outbreaks in the Democratic Republic of Congo.

However, those vaccines target the Zaire ebolavirus species. The current outbreak involves the Sudan ebolavirus species, against which existing vaccines provide no protection. While researchers have worked on Sudan strain vaccines, none have completed the full regulatory approval process required for widespread deployment.

"This is a predictable failure," said Dr. Peter Piot, who co-discovered Ebola and now directs the London School of Hygiene and Tropical Medicine. "We've known for decades that multiple Ebola species exist and that outbreaks can occur. The fact that we don't have approved vaccines for all major strains represents a fundamental gap in global health preparedness."

The current outbreak, centered in northeastern DRC near the Ugandan border, has infected more than 100 people with a case fatality rate exceeding 50 percent - typical for Ebola but devastating in human terms. The virus spreads through direct contact with bodily fluids of infected individuals, making healthcare workers particularly vulnerable.

Ugandan authorities have confirmed cases in border districts and implemented emergency measures including restrictions on public gatherings and intensive contact tracing. The porous border, active cross-border trade, and population movement complicate containment efforts.

Several experimental Sudan strain vaccines exist in various stages of development. The World Health Organization has indicated that clinical trials for these candidates could potentially be conducted during the outbreak itself, as was done with the Zaire strain vaccine during the West African epidemic. However, such trials require complex ethical approvals, logistics, and infrastructure that take time to establish.

"We may be able to deploy investigational vaccines under compassionate use protocols," said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. "But this is far from ideal. We should have had these tools ready before the outbreak began, not scrambling to develop them in the midst of an emergency."

The pharmaceutical industry's reluctance to invest in vaccines for diseases that primarily affect poor countries has been a longstanding challenge. Ebola outbreaks are sporadic and geographically limited, making them commercially unattractive despite their devastating impact on affected communities.

The Coalition for Epidemic Preparedness Innovations (CEPI), created after the West African epidemic to fund vaccine development for emerging infectious diseases, has supported Sudan strain vaccine research. However, moving candidates from development through clinical trials to regulatory approval and manufacturing scale-up requires years and hundreds of millions of dollars.

The current outbreak is also occurring in a degraded global health context. The U.S. administration has cut funding to international health organizations, including WHO and USAID global health programs. Congressional Republicans have questioned whether the U.S. should fund pandemic preparedness efforts abroad, arguing resources should focus on domestic priorities.

"We're seeing the consequences of short-term thinking," said Dr. Tom Frieden, former director of the U.S. Centers for Disease Control and Prevention. "Infectious diseases don't respect borders. An outbreak in Congo can reach anywhere in the world within 24 hours of air travel. Cutting international health programs doesn't make Americans safer - it makes everyone more vulnerable."

Neighboring countries have placed health systems on alert. Rwanda, South Sudan, and Burundi have intensified surveillance and begun preparing isolation facilities. The risk of wider regional spread depends largely on how quickly the outbreak can be contained at its source.

Health workers in affected areas face enormous challenges. Personal protective equipment is in limited supply, healthcare facilities lack basic resources, and community trust is fragile following years of conflict and exploitation. In some areas, armed groups control territory, preventing access to affected populations.

The outbreak also highlights broader questions about global health equity. Wealthy nations developed and stockpiled COVID-19 vaccines within a year of the pandemic beginning, yet diseases that primarily affect poor countries languish without adequate research funding or commercial interest.

"If Ebola outbreaks occurred regularly in Europe or North America, we would have vaccines for every known strain," said Dr. Joanne Liu, former international president of Médecins Sans Frontières. "The fact that we don't is a reflection of whose lives are valued in global health decision-making."

Some progress has been made since the West African epidemic. International response networks are better established, diagnostic capabilities have improved, and treatment protocols including experimental therapeutics like monoclonal antibodies are more advanced. These tools can reduce mortality even without vaccines.

However, vaccines remain the most effective tool for controlling Ebola outbreaks through ring vaccination strategies - immunizing contacts of confirmed cases and their contacts to create protective barriers around infection chains. Without vaccines, containment depends entirely on identifying and isolating cases before they spread, a far more difficult task.

As the outbreak continues, health officials emphasize that rapid containment is still possible with sufficient resources and political commitment. The question is whether the international community will provide that support, or whether another preventable tragedy will unfold because vaccines that could have been developed weren't deemed commercially viable - a calculation that values profit over the lives of some of the world's most vulnerable people.